The osteosarcoma is a primary bone cancer most frequently affecting children and young adolescents. It is a complex disease with manifold numerical and structural genomic alterations affecting multiple genes to a varying extent. This genomic diversity hampers the identification of reliable biomarkers to guide therapy or predict prognosis at time of diagnosis. Consequently, patients diagnosed with osteosarcoma recieve a multiagent chemotherapy independent of its necessity.